24/04/2014 07:22:23 Free Membership Login

ARK Therapeutics Company Financial Information

 Company name: Ark Ther Grp
 EPIC: AKT Trading Currency: GBX
 Market Sector: ON10 ISIN: GB0034251727
 Market Segment: SET3 Share Type: DE
 WWW Address: http://www.arktherapeutics.com/ Description: ORD 1P
 Price Price Change [%] Bid Ask Open High Low Volume
 0.54 mages.advfn.com/imagesnew/2/us/dot 0.0 [0.00] - - - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 1.12 209.28 0.07 6.20 - 0.09 - 0.80 - -

ARK Therapeutics Key Figures

(at previous day's close)
Market Cap.1.12m
Shares In Issue209.28m
Prev. Close0.54
PE Ratio0.09 
Dividend Yield-%
EPS - basic6.20p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-3.54p
Return On Equity (ROE)-462.55%
Operating Margin-713.04%
PEG Factor0.00 
EPS Growth Rate210.00%
Dividends PS Growth Rate-%
Net Debt0.90m
Gross Gearing51.78%
Quick Assets2.47m
Net Working Capital0.36m
Intangibles / Fixed Assets13.67%
Turnover PS0.87p
Pre-Tax Profit PS-6.19p
Retained Profit PS-6.08p
Cash PS0.98p
Net Cash PS-0.08p
Net Tangible Asset Value PS *1.11p
Net Asset Value PS1.32p
Spread- (-%) 

ARK Therapeutics Balance Sheet


ARK Therapeutics Share Price

Sample Period HighLow
1 week--
4 weeks0.54-
12 weeks0.58-
1 year0.80-

ARK Therapeutics Share Price (5 years)

ARK Therapeutics Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week-0.54----
4 weeks0.54--0.54--
12 weeks0.340.2059.700.471.640.43
26 weeks0.360.1848.610.391.200.39
1 year0.360.1850.700.411.040.41
3 years4.33-3.79-87.632.300.861.21
5 years50.00-49.47-98.939.160.653.48

ARK Therapeutics Key Management Ratios

ARK Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio0.09 
Tobin's Q Ratio 0.09 
Tobin's Q Ratio (excl. intangibles)0.09 
Dividend Yield-%
Market-to-Book Ratio0.41 
Price-to-Pre-Tax Profit PS-0.09 
Price-to-Retained Profit PS-0.09 
Price-to-Cash Flow PS-0.15 
Price-to-Sales PS0.62 
Price-to-Net Tangible Asset Value PS0.48 
Price-to-Cash PS0.54 
Net Working Capital PS0.17 
Price Pct to Working Capital PS3.14%
Earnings Yield1,158.88%
Average PE0.90 
Years in average3 
PE to PE average9.61%

ARK Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio20.89%
Debt-to-Equity Ratio0.26 
Debt-to-Equity Ratio (excl. Intgbl)0.31 
Debt-to-Equity Market Value0.65 
Net Gearing15.78%
Net Gearing (excl. Intangibles)17.06%
Gross Gearing51.78%
Gross Gearing (excl. Intangibles)55.96%
Gearing Under 1 Year39.04%
Gearing Under 1 Year (excl. Intgbl)42.20%
(Liquidity Ratios)
Net Working Capital to Total Assets6.25%
Current Ratio1.16 
Quick Ratio (Acid Test)1.11 
Liquidity Ratio0.92 
Cash & Equiv/Current Assets79.47%
(Solvency Ratios)
Enterprise Value-0.21m
CFO/Attributable Profit- 
Total Debt/Equity Market Value2.64 
Total Debt/Sales1.63 
Total Debt/Pre-Tax Profit-0.23 
Total Debt2.96m
Total Debt/Net Current Assets8.28%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs3 
Beta (60-Mnth)Beta (36-Mnth)
Alpha (60-Mnth)Alpha (36-Mnth)

ARK Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-372.50%
Return On Assets (ROA)-98.49%
Net Profit Margin-700.44%
Assets Turnover0.14 
Return On Equity (ROE)-462.55%
Return On Investment (ROI)-128.81%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-140.05%
Net Income Of Revenues-700.44%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.20 
Fixed Assets Turnover0.31 
Current Assets Turnover0.26 
Net Working Capital Turnover 
Inventory Turnover10.42 
(Other Operating Ratios)
Total Assets-to-Sales7.11 
Debt Collection Period235.60Days

ARK Therapeutics Dividends

Sorry No Data Available

ARK Therapeutics Fundamentals

 31 Dec 2009 (GBP)31 Dec 2010 (GBP)31 Dec 2011 (GBP)31 Dec 2012 (GBP)
pre tax profit-21.15-713.66%-16.94--4.44-62.34%-12.96-713.04%m
attributable profit-19.87-670.24%-16.17--3.45-48.39%-12.73-700.44%m
retained profit-19.87-670.24%-16.17--3.45-48.39%-12.73-700.44%m
eps - basic-10.00 8.00 2.00 6.20 
eps - diluted-10.00 8.00 2.00 6.20 
dividends per share- - - - 

ARK Therapeutics Balance Sheet

 31 Dec 2009 (GBP)31 Dec 2010 (GBP)31 Dec 2011 (GBP)31 Dec 2012 (GBP)
 31 Dec 2009 (GBP)31 Dec 2010 (GBP)31 Dec 2011 (GBP)31 Dec 2012 (GBP)
fixed assets fixed assets12.1229.19%9.1137.46%6.7033.26%2.7047.22%m
intangibles intangibles3.518.47%1.947.96%1.798.87%0.437.48%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%1.004.10%--%--%m
stocks stocks0.431.03%--%0.231.15%0.122.05%m
debtors debtors18.5944.78%4.5618.75%1.939.59%0.417.25%m
cash & securities cash & securities6.8716.54%7.7231.73%9.5047.13%2.0636.00%m
creditors - short creditors - short3.859.27%3.9116.07%3.8619.15%2.2339.04%m
creditors - long creditors - long2.125.10%1.626.64%0.864.27%0.7312.73%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves35.5585.63%18.8077.28%15.4376.59%2.7548.22%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

ARK Therapeutics Cash Flow Statement

31 Dec 2009 (GBP)31 Dec 2010 (GBP)31 Dec 2011 (GBP)31 Dec 2012 (GBP)
Operating CF-19.48-10.73-1.65-7.40m
Pre-Financing CF-0.580.851.74-7.30m
Retained CF-0.300.831.75-7.48m

ARK Therapeutics Brokers

Nomura Code Securities LimitedMarket Maker(MME)Broker/DealerCODECODCGB21
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MME)Broker/DealerJEFFJEFFGB2X
Piper Jaffray LtdMarket Maker(MME)Broker/DealerPIPRPIPRGB21
Numis Securities LimitedMarket Maker(MME)Broker/DealerNUMSRAZHGB2LBIC
Merrill Lynch InternationalMarket Maker(MME)Broker/DealerMLSBSNCSGB2LBIC
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse akt140424 07:22